Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 57

Results For "advance"

2857 News Found

BioAsia 2026 cements Telangana’s global leadership in TechBio and life sciences
News | February 19, 2026

BioAsia 2026 cements Telangana’s global leadership in TechBio and life sciences

40+ most innovative startups with disruptive contributions across MedTech, Medical Devices, BioPharma, Cell and Gene Therapy, AI and ML, Nutraceuticals, and Biomarkers exhibited their cutting-edge solutions


Lilly breakthrough: Dual treatment clears skin & cuts weight in psoriasis patients
Clinical Trials | February 19, 2026

Lilly breakthrough: Dual treatment clears skin & cuts weight in psoriasis patients

The trial targeted a patient population with high BMI and extensive skin involvement, averaging over 39 kg/m²


GSK’s Exdensur wins EU nod for severe asthma
News | February 19, 2026

GSK’s Exdensur wins EU nod for severe asthma

The approval is based on the SWIFT and ANCHOR phase III trials, which demonstrated sustained efficacy with a twice-yearly dosing regimen


Evinova teams up with Astellas, AstraZeneca & Bristol Myers Squibb to supercharge clinical trials with AI
Digitisation | February 19, 2026

Evinova teams up with Astellas, AstraZeneca & Bristol Myers Squibb to supercharge clinical trials with AI

Each company will share operational data with Evinova, feeding the platform’s AI engines to provide benchmarks and actionable insights, aiming to speed up trials while maintaining top-tier patient care


Evogene and QUT join forces to tackle chemotherapy-resistant lung cancer with AI
R&D | February 18, 2026

Evogene and QUT join forces to tackle chemotherapy-resistant lung cancer with AI

Dr Adams’ lab recently uncovered a novel cellular detoxification pathway driving Cisplatin resistance in NSCLC


Newron Pharmaceuticals bags up to €38 million to fuel Phase III ENIGMA-TRS program
Biopharma | February 18, 2026

Newron Pharmaceuticals bags up to €38 million to fuel Phase III ENIGMA-TRS program

A final tranche of €12 million will follow, contingent on positive pivotal study results, with the share price calculated according to an agreed formula